Cytokine Signalling Forum

Publications




Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials

Salvarani C, Sebastiani M, Dieude P, Garcia M, Deberdt W, Rogai V, de la Torre I, Inciarte-Mundo J, Balsa A. - Rheumatol Ther. 2021 Jun 28. DOI: 10.1007/s40744-021-00332-w

Findings from a descriptive clinical case report from clinical trials show that patients with RA, treated with baricitinib, are at low risk to developing non-infectious interstitial lung disease (ILD) during treatment.

Salvarani, et al. used a descriptive, multicentric, retrospective cohort study of eight randomised trials and one long-term extension study to estimate the number of incident ILD cases reported.

Their findings showed that the risk of developing non-infectious ILD during baricitinib treatment was similar to that observed with other JAK inhibitors.

Access original article via Pubmed

Upload date: August 2021

Article image